Therefore, the most recent TCGA database from 594 patients (September 2017) (https://tcga-data.nci.nih.gov/tcga/) was analyzed, and Ptp4a3 amplification in ∼33% of the ovarian serous cystadenocarcinomas (Figure 1A) and exceptionally high mRNA expression compared to the 13,860 genes examined in the companion RNASeqV2 data from 307 TCGA OvCa patients was confirmed (Figure 1B, Supplementary Figure 1A). The gene discussed is PTP4A3; the disease is ovarian serous cystadenocarcinoma.